Outlook Therapeutics, Inc. Quarterly Debt-to-equity in % from Q4 2016 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Outlook Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q4 2016 to Q2 2024.
  • Outlook Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was -162 %, a 130% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 -162 -706 -130% Jun 30, 2024
Q1 2024 -188 -422 -180% Mar 31, 2024
Q4 2023 -551 -696 -480% Dec 31, 2023
Q3 2023 2.97K +2.88K +3276% Sep 30, 2023
Q2 2023 543 +454 +505% Jun 30, 2023
Q1 2023 234 +136 +139% Mar 31, 2023
Q4 2022 145 +38.5 +36.1% Dec 31, 2022
Q3 2022 87.9 -224 -71.8% Sep 30, 2022
Q2 2022 89.8 -238 -72.6% Jun 30, 2022
Q1 2022 97.8 -251 -72% Mar 31, 2022
Q4 2021 107 +646 Dec 31, 2021
Q3 2021 312 +592 Sep 30, 2021
Q2 2021 328 +534 Jun 30, 2021
Q1 2021 349 +527 Mar 31, 2021
Q4 2020 -540 -370 -218% Dec 31, 2020
Q3 2020 -281 -95.4 -51.5% Sep 30, 2020
Q2 2020 -206 -23.5 -12.9% Jun 30, 2020
Q1 2020 -178 +1.01 +0.56% Mar 31, 2020
Q4 2019 -170 +2.43 +1.41% Dec 31, 2019
Q3 2019 -185 -11 -6.34% Sep 30, 2019
Q2 2019 -183 -13.9 -8.23% Jun 30, 2019
Q1 2019 -179 -30 -20.1% Mar 31, 2019
Q4 2018 -172 -13.1 -8.22% Dec 31, 2018
Q3 2018 -174 -8.75 -5.29% Sep 30, 2018
Q2 2018 -169 +28.4 +14.4% Jun 30, 2018
Q1 2018 -149 +135 +47.5% Mar 31, 2018
Q4 2017 -159 +77.4 +32.7% Dec 31, 2017
Q3 2017 -165 Sep 30, 2017
Q2 2017 -197 Jun 30, 2017
Q1 2017 -284 Mar 31, 2017
Q4 2016 -236 Dec 31, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.